The Chinese Consume...
Health Care: Health Services
St Jude Medical Inc. (STJ: NYSE)
$43.51 0.09 | 0.21%
02/08/12 - 04:02 PM ET
3.27M / 3.99M
Vol / Avg. Vol:43.37 / 43.42
Open / Prev. Close:43.04 - 43.51
Today's Range:32.13 - 54.18
52 Wk Range:26.85%
Performance YTD:TheStreet Rating:
Portfolios with STJ
- Portfolio NameUser Type
- Contributor10 Health Care Stocks to Watch
- UserSTRG BUY
- ContributorTop-Yielding Health Service...
- Contributor10 Stocks Gloomy Goldman Sa...
- ProBill Frels - Mairs & Po...
- ProViking Global Investors
- UserGeneral
- ContributorStocks With Notable Insider...
- ProEdward Owens
- ContributorJefferies' 6 Best Health-Ca...
Latest STJ Headlines from TheStreet
- 10 Health Care Stocks to Watch 01.27.12 | 05:01 pm
- Pharmaceutical Earnings Outlook
01.26.12 | 09:01 am - St. Jude Medical's CEO Discusses Q4 2011 Results - Earnings Call Transcript 01.25.12 | 02:01 pm
- St Jude Medical Inc. (STJ): Today's Featured Health Services Loser 12.16.11 | 04:12 pm
- St Jude Medical Inc. (STJ): Today's Featured Health Services Loser 12.09.11 | 04:12 pm
- Gloomy Goldman Sachs Is Bullish on These 10 Stocks 12.08.11 | 10:12 am
- St Jude Medical Inc. (STJ): Today's Featured Health Care Loser 12.02.11 | 05:12 pm
- St Jude Medical Inc. (STJ): Today's Featured Health Services Loser 11.17.11 | 05:11 pm
- Analysts' Actions: F, AMZN, URBN, CVX, APC 11.08.11 | 08:11 am
- Analysts' Actions: MA, TEVA, SIRI, IBM, AAPL 11.03.11 | 09:11 am
Press Releases for STJ
- St. Jude Medical Reports Fourth Quarter And Full-Year 2011 Results - Business Wire 01.25.12 | 07:01 am
- Independent Data Safety Monitoring Board Recommends St. Jude Medical’s FAME II Clinical Trial Stop Enrollment Following Positive Interim Analysis - Business Wire 01.18.12 | 08:01 am
- Data From St. Jude Medical’s ASSERT Implantable Device Monitoring Study Published In New England Journal Of Medicine - Business Wire 01.12.12 | 10:01 am
- The Libra(TM) Deep Brain Stimulation (DBS) System Is Approved In Europe And Australia For Treating The Symptoms Of Parkinson's Disease And Is Being Evaluated In U.S. Clinical Trials For Parkinson's Disease And Essential Tremor. (Photo: St. Jude Medical Inc.) - Business Wire 01.11.12 | 08:01 am
- St. Jude Medical Announces Preliminary Fourth Quarter Revenue Results - Business Wire 01.09.12 | 09:01 am
- Proposed St. Jude Medical Expansion - Plymouth Campus (Graphic: St. Jude Medical, Inc.) - Business Wire 01.04.12 | 02:01 pm
- St. Jude Medical To Present At The 30th Annual J.P. Morgan Healthcare Conference - Business Wire 01.04.12 | 07:01 am
- St. Jude Medical Announces Achievement Of Stopping Rule And Closing Of Patient Enrollment In RESPECT Clinical Trial - Business Wire 01.03.12 | 04:01 pm
- St. Jude Medical Launches Riata Communication Website - Business Wire 12.21.11 | 12:12 pm
- FDA Classifies Voluntary Physician Advisory Letter On Riata And Riata ST Silicone Defibrillation Leads As Class I Recall (URGENT MEDICAL DEVICE ADVISORY) - Business Wire 12.15.11 | 05:12 pm
Partner Headlines for STJ
- Earnings Scorecard: St. Jude - Analyst Blog - Zacks 02.03.12 | 07:02 pm
- The Zacks Analyst Blog Highlights: Medtronic, Edwards Lifesciences, Boston Scientific, St Jude Medical and Southwest Airlines - Press Releases - Zacks 02.03.12 | 09:02 am
- Boston Scientific: Struggles Today, Still Hope For Tomorrow? - Seeking Alpha 02.02.12 | 08:02 am
- Covidien Plays To Its Strengths And Still Looks Undervalued - Seeking Alpha 01.27.12 | 08:01 am
- The Zacks Analyst Blog Highlights: Medtronic, Edwards Lifesciences, Boston Scientific, St Jude Medical and CA - Press Releases - Zacks 01.26.12 | 09:01 am
- Goldman Sachs Maintains St. Jude Medical Neutral, $38 PT - Benzinga 01.25.12 | 04:01 pm
- Zacks Bull and Bear of the Day Highlights: Caterpillar, NII Holdings, Lowe's Companies, Home Depot and St. Jude Medical - Press Releases - Zacks 01.24.12 | 09:01 am
- Earnings Expectations for the Week of January 23 - Benzinga 01.22.12 | 02:01 pm
- Piper Jaffray Gives Insight to Medical Technology Industry Overview - Benzinga 01.17.12 | 09:01 am
- St. Jude Posts In-Line Prelim Sales - Analyst Blog - Zacks 01.10.12 | 10:01 am
